Radiation therapy in locally advanced rectal cancer

Feasibility and toxicity of dose escalated radiation therapy in locally advanced rectal cancer - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059109

Enrollment

Registered

2023-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Dose escalated radiation therapy in locally advanced rectal cancer: In locally advanced rectal cancer i.e. cT3,T4/N+, Adenocarcinoma, pt will be treated with neoadjuvant chemoradiothera

Eligibility

Inclusion criteria

Inclusion criteria: -Histologically proven cases of rectal adenocarcinoma -AJCC 2018 Stage T3,T4 and/or positive LN Status -Age 18-65 years -ECOG 0-2 -Normal Haematological profile(Hb >10g/dl, TLC >4000,Platelet >100000) -Normal renal and liver function tests -Patient willing to participate in the study

Exclusion criteria

Exclusion criteria: -Patient having two primary malignancy at the same time -Patient having history of prior chemotherapy or RT

Design outcomes

Primary

Measure	Time frame
To assess feasibility and toxicity of dose escalated radiation therapy in locally advanced rectal cancerTimepoint: Acute toxicity will be assessed weekly throughout RT, monthly upto 3 months after completion of RT	—

Secondary

Measure	Time frame
Pathological response Local regional control Disease free survival Overall survivalTimepoint: Pathological complete response will be assessed after 6-8 weeks of RT after surgery	—

Countries

India

Contacts

Public ContactDr Himanshu Mishra

Department of radiotherapy and radiation medicine IMS,BHU

hmsra1801@gmail.com7704909900

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026